In conclusion, similarly to roscovitine, targeting PCNA in neutrophils using the p21 competing peptide could accelerate the resolution of inflammation in an infectious context and could be considered as a potential therapeutic strategy in CF. Here, CDKN1A is linked to cystic fibrosis.